IMRX vs LLY
IMRX: Immuneering is a clinical-stage oncology company developing a new class of Deep Cyclic Inhibitors designed to overcome the limitations of chronic targeted therapies in cancer treatment. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | IMRX | LLY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.74 | $1,169.60 | |
| Market cap | $242M | $1.10T | |
| P/E as of 2026-10-08 | n/a | 39.25 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.80 | |
| Net margin FY2025, SEC XBRL | n/a | +31.7% | |
| ROE FY2025, SEC XBRL | -25.6% | +77.8% | LLY higher |
| ROA FY2025, SEC XBRL | -24.2% | +18.4% | LLY higher |
| Debt / equity as of 2026-09-02 | 0.00 | 1.62 | IMRX lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +49.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +31.7% | |
| Dividend yield as of 2026-09-03 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | 10 | LLY higher |
| Beta as of 2026-09-02 | 0.91 | 0.55 | |
| 1-year return as of 2026-10-08 close | -42.5% | +38.3% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.